Naturally occurring mutations to HCV protease inhibitors in treatment-nave patients

Virology Journal

Volumn 9, Issue , 2012, Pages

  Paolucci, Stefania ^a   Fiorina, Loretta ^a   Piralla, Antonio ^a   Gulminetti, Roberto ^b   Novati, Stefano ^b   Barbarini, Giorgio ^a   Sacchi, Paolo ^a   Gatti, Marta ^a   Dossena, Luca ^a   Baldanti, Fausto ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Genetic diversity; HCV baseline resistance; Hepatitis C virus; HIV HCV co infection; Protease inhibitors

Indexed keywords

NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN;

AMINO ACID SUBSTITUTION; ARTICLE; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PROSPECTIVE STUDY;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CLUSTER ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MUTATION, MISSENSE; PHYLOGENY; POLYMORPHISM, GENETIC; PROTEASE INHIBITORS; SEQUENCE HOMOLOGY; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84867679786     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-245     Document Type: Article

References (32)

1. Hepatitis C virus infection. Lauer GM, Walker BD, N Engl J Med 2001 345 41 52 10.1056/NEJM200107053450107 11439948 (Pubitemid 32634271)
2. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK, Lancet 2001 358 958 965 10.1016/S0140-6736(01)06102-5 11583749 (Pubitemid 32913521)
3. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group, Ann Intern Med 2004 140 346 355 14996676
4. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a and 6a NS3/4A protease recombinant viruses. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J, Gastroenterology 2011 141 1067 1079 10.1053/j.gastro.2011.06.004 21699793
5. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD, Gastroenterology 2007 132 1767 1777 10.1053/j.gastro.2007.02.037 17484874 (Pubitemid 46677938)
6. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S, Hepatology 2007 46 631 639 10.1002/hep.21781 17680654 (Pubitemid 47436107)
7. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Fanning GC, Simmen KA, Antimicrob Agents Chemother 2010 54 1878 1887 10.1128/AAC.01452-09 20176898
8. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Romano KP, Ali A, Royer WE, Schiffer CA, PNAS 2010 107 20986 20991 10.1073/pnas.1006370107 21084633
9. Hepatitis C virus resistance to protease inhibitors. Halfon P, Locarnini S, J Hepatol 2011 55 192 206 10.1016/j.jhep.2011.01.011 21284949
10. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Lápez-Labrador FX, Moya A, Gonzlez-Candelas F, Antivir Therapy 2008 13 481 494 (Pubitemid 352016711)
11. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH503034). Flint M, Mullen S, Deatly AM, Chen W, Miller LZ, Ralston R, Broom C, Emini EA, Howe AY, Antimicrob Agents Chemother 2009 53 401 411 10.1128/AAC.01081-08 18936191
12. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C, Hepatology 2009 50 1709 1718 10.1002/hep.23192 19787809
13. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. Verbinnen T, Van Marck H, Vandenbroucke I, Vijgen L, Claes M, Lin TI, Simmen K, Neyts J, Fanning G, Lenz O, J Virol 2010 84 11124 11133 10.1128/JVI.01217-10 20739521
14. Computational study of the effects of mutations A156T, D168V, and D168Q on the binding of HCV protease inhibitors. Guo Z, Prongay A, Tong X, Fischmann T, Bogen S, Velazquez F, Venkatraman S, Njoroge FG, Madison V, J Chem Theory Comput 2006 2 1657 1663 10.1021/ct600151y
15. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). Thompson AJ, McHutchison JG, J Viral Hepat 2009 16 377 387 10.1111/j.1365-2893. 2009.01124.x 19472445
16. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-nave patients. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM, Hepatology 2008 48 1769 1778 10.1002/hep.22549 19026009
17. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. Trimoulet P, Belzunce C, Faure M, Wittkop L, Reigadas S, Dupon M, Ragnaud JM, Fleury H, Neau D, HIV Med 2011 12 506 509 10.1111/j.1468-1293.2011.00913.x 21410862
18. Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy. Halfon P, Bourlière M, Khiri H, Pénaranda G, Martineau A, Oulès V, Courcambeck J, Philibert P, AIDS 2008 22 1694 1696 10.1097/QAD.0b013e32830a989b 18670239
19. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy. Morsica G, Bagaglio S, Uberti-Foppa C, Galli L, Lazzarin A, J Acquir Immune Defic Syndr 2009 51 106 108 10.1097/QAI.0b013e3181a02fda 19390331
20. MEGA5: molecular evolutionary genetics analysis using maximumlikelihood, evolutionary distance, and maximum parsimony methods. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S, Mol Biol Evol 2011 28 2731 2739 10.1093/molbev/msr121 21546353
21. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Pawlotsky JM, Hepatology 2011 53 1742 1751 10.1002/hep.24262 21374691
22. Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease. Welsch C, Schweizer S, Shimakami T, Domingues FS, Kim S, Lemon SM, Antes I, Antimicrob Agents Chemother 2012 56 1907 1915 10.1128/AAC.05184-11 22252823
23. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. Thibeault D, Bousquet C, Gingras R, Lagacé L, Maurice R, White PW, Lamarre D, J Virol 2004 78 7352 7359 10.1128/JVI.78.14.7352-7359.2004 15220408 (Pubitemid 38915881)
24. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Zhou Y, Bartels DJ, Hanzelka BL, Müh U, Wei Y, Chu HM, Tigges AM, Brennan DL, Rao BG, Swenson L, Kwong AD, Lin C, Antimicrob Agents Chemother 2008 52 110 120 10.1128/AAC.00863-07 17938182
25. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. Lin C, Luong YP, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell KM, Perni RB, Gates CA, Kwong AD, J Biol Chem 2004 279 17508 17514 10.1074/jbc.M313020200 14766754 (Pubitemid 38560514)
26. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. Yi M, Tong X, Skelton A, Chase R, Chen T, Prongay A, Bogen SL, Saksena AK, Njoroge FG, Veselenak RL, Pyles RB, Bourne N, Malcolm BA, Lemon SM, J Biol Chem 2006 281 8205 8215 10.1074/jbc.M510246200 16352601 (Pubitemid 43847441)
27. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease. Liu R, Abid K, Pichardo J, Pazienza V, Ingravallo P, Kong R, Agrawal S, Bogen S, Saksena A, Cheng KC, Prongay A, Njoroge FG, Baroudy BM, Negro F, J Antimicrob Chemother 2007 59 51 58 17151003 (Pubitemid 46017900)
28. Combined antiretroviral treatment initiation during hospitalization: outcomes in South African adults. Eshun-Wilson I, Plas HV, Prozesky HW, Zeier MD, Nachega J, Taljaard JJ, JAIDS 2009 51 106 108 10.1097/QAI.0b013e3181a02fda 19390331
29. Molecular characterization of HCV genotype 4 isolates circulating in Italy. Argentini C, Dettori S, Villano U, Guadagnino V, Infantolino D, Dentico P, Coppola RC, Rapicetta M, J Med Virol 2000 62 84 90 10.1002/1096-9071(200009) 62:1<84::AID-JMV13>3.0.CO;2-E 10935993
30. Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients. Vallet S, Gouriou S, Nousbaum JB, Legrand-Quillien MC, Goudeau A, Picard B, J Med Virol 2005 75 528 537 10.1002/jmv.20302 15714495 (Pubitemid 40293520)
31. Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus. Winters MA, Welles SL, Holodniy M, J Virol 2006 80 4196 4199 10.1128/JVI.80.8.4196-4199.2006 16571838
32. Genetic and catalytic efficiency structure of an HCV protease quasispecies. Franco S, Parera M, Aparicio E, Clotet B, Martinez MA, Hepatology 2007 45 899 910 10.1002/hep.21623 17393500 (Pubitemid 46631559)